WELVASTA-20 contains Rosuvastatin 20 mg, formulated for intensive LDL-cholesterol reduction and cardiovascular risk management in appropriate patients. A strong PCD Cardiac-Diabetic lipid-management brand.
It provides greater LDL-lowering intensity than lower doses.
Unexplained muscle pain or weakness.
Follow the prescribed dose and lipid monitoring plan. Report severe muscle symptoms or jaundice promptly.
Headache, nausea, abdominal discomfort and muscle pain; liver enzyme elevation and rare serious muscle injury may occur. (DailyMed)
WELVASTA-20: Rosuvastatin inhibits HMG-CoA reductase, substantially reducing hepatic cholesterol production and enhancing LDL removal from circulation.
